PACIRA BIOSCIENCES, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
PACIRA BIOSCIENCES, INC. (PCRX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $16.44 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $15.14.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $27.64, a 19.37% decline year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-03-31 was $34.28, a 0.73% increase year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $34.03.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $16.45.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $30.93, a 12.55% decline from fiscal 2022.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $35.37, a 8.63% increase from fiscal 2021.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $32.56, a 2.81% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.44 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $15.14 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | $16.45 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $15.14 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $30.93 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $30.93 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $30.91 10-Q · filed 2023-08-02 | |||
| 2023-03-31 | $27.64 10-Q · filed 2023-05-03 | |||
| 2022-12-31 | $35.37 10-K · filed 2024-02-29 | |||
| 2022-09-30 | $35.18 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $34.80 10-Q · filed 2022-08-03 | |||
| 2022-03-31 | $34.28 10-Q · filed 2022-05-04 | |||
| 2021-12-31 | $32.56 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $34.43 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | $33.42 10-Q · filed 2021-08-03 | |||
| 2021-03-31 | $34.03 10-Q · filed 2021-05-04 | |||
| 2020-12-31 | $31.67 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $32.08 10-Q · filed 2020-10-30 | |||
| 2020-06-30 | $27.26 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |